Janssen unveils data from first phase-3 trial of single-tablet regimen
Category: #health  By Pankaj Singh  Date: 2019-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Janssen unveils data from first phase-3 trial of single-tablet regimen

The outcomes from the first prospective Phase 3 trial studying the rapid initiation of a single-tablet regimen were published at the 13th ACTHIV 2019 conference

Janssen Pharmaceutical Companies of Johnson & Johnson has reportedly released new 48-week data for SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF). As per trusted sources, the data demonstrates that a high proportion of HIV patients attained an undetectable viral load through 48 weeks following the rapid start of SYMTUZA®.

According to a press release by Janssen, a secondary endpoint of the study also revealed that 97 percent of patients stated they were gratified with the treatment. The outcomes from the first prospective Phase 3 trial studying the rapid initiation of a single-tablet regimen – DIAMOND study – were published at the 13th Annual American Conference for the Treatment of HIV (ACTHIV 2019) in Miami, Florida.

Infectious Disease Director of Midway Immunology and Research Center at Fort Pierce, Florida, Moti Ramgopal, M.D., was reportedly quoted saying that the rapid initiation of antiretroviral treatment is becoming the recognized standard of care for newly diagnosed HIV-1 patients since it can enhance treatment outcomes.

It includes the probability of an individual adhering to treatment and staying in care. Moreover, it can be an additional strategy in the firm’s goal to achieve the 90/90/90 prevention and treatment goals as outlined by UNAIDS, Ramgopal further added.

Reportedly, the DIAMOND study assessed the once-daily STR SYMTUZA® to treat HIV type 1 (HIV-1) infection in adult patients who had signed up within 14 days of obtaining an HIV diagnosis. All these patients then commenced the intake of SYMTUZA® before laboratory or baseline resistance test outcomes were made available.

The U.S. Food & Drug Administration (FDA) has approved SYMTUZA® for the treatment of HIV-1 infection in certain virologically suppressed and treatment-naïve adults.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Acadia announces positive results of Phase 3 trial to treat psychosis
Acadia announces positive results of Phase 3 trial to treat psychosis
By Pankaj Singh

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY stu...

Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.
Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.
By Pankaj Singh

Senseonics Holdings, Inc., a US-based medical device startup company recently announced that users of its Eversense CGM (continuous glucose monitoring) system can now use the new Eversense CGM mobile application f...

Astellas Pharma inks a $3 Bln deal to acquire Audentes Therapeutics
Astellas Pharma inks a $3 Bln deal to acquire Audentes Therapeutics
By Pankaj Singh

Japanese pharmaceutical company, Astellas Pharma Inc. has reportedly entered into a definitive agreement to acquire biotech firm Audentes Therapeutics, Inc. at a price of US$60.00 per share in cash, representing equity...